{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T21:10:06Z","timestamp":1759093806259,"version":"3.44.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015237","name":"Medicines Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015237","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.ijcard.2020.03.065","type":"journal-article","created":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T10:52:26Z","timestamp":1585565546000},"page":"37-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Twelve-month mortality from the \u201cHow Effective are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention (HEAT-PPCI) Trial\u201d"],"prefix":"10.1016","volume":"310","author":[{"given":"Sarah R.","family":"Blake","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adeel","family":"Shahzad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Kemp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Mars","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rod H.","family":"Stables","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2020.03.065_bb0005","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3389\/fphar.2017.00410","article-title":"Safety and effectiveness of Bivalirudin in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis","volume":"8","author":"Ahmad Hamdi","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"6","key":"10.1016\/j.ijcard.2020.03.065_bb0010","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.21037\/jtd.2018.05.76","article-title":"Bivalirudin versus heparin in percutaneous coronary intervention-a systematic review and meta-analysis of randomized trials stratified by adjunctive glycoprotein IIb\/IIIa strategy","volume":"10","author":"Anantha-Narayanan","year":"2018","journal-title":"J. Thorac. Dis."},{"issue":"2","key":"10.1016\/j.ijcard.2020.03.065_bb0015","doi-asserted-by":"crossref","first-page":"196","DOI":"10.4244\/EIJY14M08_01","article-title":"Bivalirudin versus heparin in patients treated with percutaneous coronary intervention: a meta-analysis of randomised trials","volume":"11","author":"Cassese","year":"2015","journal-title":"EuroIntervention"},{"issue":"12","key":"10.1016\/j.ijcard.2020.03.065_bb0020","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa1706443","article-title":"Bivalirudin versus heparin monotherapy in myocardial infarction","volume":"377","author":"Erlinge","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.ijcard.2020.03.065_bb0025","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003515","article-title":"Prolonged high-dose bivalirudin infusion reduces major bleeding without increasing stent thrombosis in patients undergoing primary percutaneous coronary intervention: novel insights from an updated meta-analysis","volume":"5","author":"Fahrni","year":"2016","journal-title":"J. Am. Heart Assoc."},{"issue":"13","key":"10.1016\/j.ijcard.2020.03.065_bb0030","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1001\/jama.2015.2323","article-title":"Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial","volume":"313","author":"Han","year":"2015","journal-title":"Jama"},{"issue":"9","key":"10.1016\/j.ijcard.2020.03.065_bb0035","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00392-018-1251-1","article-title":"Efficacy and safety of bivalirudin for percutaneous coronary intervention in acute coronary syndromes: a meta-analysis of randomized-controlled trials","volume":"107","author":"Nuhrenberg","year":"2018","journal-title":"Clin. Res. Cardiol."},{"issue":"23","key":"10.1016\/j.ijcard.2020.03.065_bb0040","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa1311096","article-title":"Bivalirudin started during emergency transport for primary PCI","volume":"369","author":"Steg","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.ijcard.2020.03.065_bb0045","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","article-title":"Bivalirudin during primary PCI in acute myocardial infarction","volume":"358","author":"Stone","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.ijcard.2020.03.065_bb0050","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1507854","article-title":"Bivalirudin or unfractionated heparin in acute coronary syndromes","volume":"373","author":"Valgimigli","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"9957","key":"10.1016\/j.ijcard.2020.03.065_bb0055","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(14)60924-7","article-title":"Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single Centre, randomised controlled trial","volume":"384","author":"Shahzad","year":"2014","journal-title":"Lancet"},{"author":"NHS D","key":"10.1016\/j.ijcard.2020.03.065_bb0060"},{"issue":"7","key":"10.1016\/j.ijcard.2020.03.065_bb0065","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1001\/jamacardio.2016.5975","article-title":"One-year mortality for bivalirudin vs heparins plus optional glycoprotein IIb\/IIIa inhibitor treatment started in the ambulance for ST-segment elevation myocardial infarction: a secondary analysis of the EUROMAX randomized clinical trial","volume":"2","author":"Fabris","year":"2017","journal-title":"JAMA Cardiol."},{"issue":"9784","key":"10.1016\/j.ijcard.2020.03.065_bb0070","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/S0140-6736(11)60764-2","article-title":"Heparin plus a glycoprotein IIb\/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial","volume":"377","author":"Stone","year":"2011","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ijcard.2020.03.065_bb0075","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2013-000021","article-title":"Major bleeding after percutaneous coronary intervention and risk of subsequent mortality: a systematic review and meta-analysis","volume":"1","author":"Kwok","year":"2014","journal-title":"Open Heart"},{"issue":"3","key":"10.1016\/j.ijcard.2020.03.065_bb0080","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jcin.2014.10.015","article-title":"Novel approaches for preventing or limiting events (Naples) III trial: randomized comparison of bivalirudin versus unfractionated heparin in patients at increased risk of bleeding undergoing transfemoral elective coronary stenting","volume":"8","author":"Briguori","year":"2015","journal-title":"JACC Cardiovasc. Interv."},{"author":"BCIS","key":"10.1016\/j.ijcard.2020.03.065_bb0085"},{"issue":"20","key":"10.1016\/j.ijcard.2020.03.065_bb0090","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1016\/j.jacc.2012.08.966","article-title":"A contemporary view of diagnostic cardiac catheterization and percutaneous coronary intervention in the United States: a report from the CathPCI registry of the National Cardiovascular Data Registry, 2010 through June 2011","volume":"60","author":"Dehmer","year":"2012","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016752731936142X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016752731936142X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T20:47:25Z","timestamp":1759092445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016752731936142X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":18,"alternative-id":["S016752731936142X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2020.03.065","relation":{},"ISSN":["0167-5273"],"issn-type":[{"type":"print","value":"0167-5273"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Twelve-month mortality from the \u201cHow Effective are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention (HEAT-PPCI) Trial\u201d","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2020.03.065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2020 Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}